A case of diffuse melanosis cutis with positive BRAF mutation status and treatment with targeted therapies

R. Minocha, P. Uribe, R. Kefford, P. Fernandez Penas

Research output: Contribution to journalMeeting abstract

Abstract

Diffuse melanosis cutis (DMC) is a rare presentation ofmetastatic melanoma associated with a particularlyguarded prognosis. The advent of target therapies hastransformed the landscape of management in patients withmetastatic melanoma, however it is yet to be determinedwhether this includes patients with a particularly poor prog-nosis such as those with DMC. We report a case of a 35 yearold male with BRAFV600Emetastatic melanoma treated withvemurafenib (as well as Ipilimumab and whole brain radio-therapy), who is alive, 25 months beyond the onset of hisDMC. This is significantly longer than the reported meansurvival of four months, further highlighting the promisingsurvival advantage of targeted therapies when compared toconventional chemotherapeutic regimens.
Original languageEnglish
Pages (from-to)41-41
Number of pages1
JournalAustralasian Journal of Dermatology
Volume55
Issue numberSupplement s1
Publication statusPublished - May 2014
Externally publishedYes

Cite this